Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022 – CDC Morbidity and Mortality Weekly Report Related: Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update. WHO Guideline: Screening for Tuberculosis Disease New WHO Recommendations to Prevent Tuberculosis CDC Guidelines for the Treatment of Latent […]

The post New CDC interim guidance recommends a 4-month Rifapentine-Moxifloxacin regimen to treat drug-susceptible pulmonary tuberculosis. appeared first on Links Medicus.